Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infection
暂无分享,去创建一个
Gheyath K Nasrallah | R. Bertollini | M. Al-Kuwari | H. Yassine | M. Al-Thani | Z. Al-Kanaani | A. Butt | A. Althani | H. Al-Romaihi | P. Coyle | A. Jeremijenko | A. Latif | H. Chemaitelly | H. Ayoub | P. Tang | M. Hasan | H. Al-Khatib | E. Al-Kuwari | A. Kaleeckal | R. Shaik | H. Abdul-Rahim | L. Abu-Raddad | A. Al-khal | L. Abu‐Raddad
[1] Gheyath K Nasrallah,et al. Covid-19 Vaccine Protection among Children and Adolescents in Qatar , 2022, The New England journal of medicine.
[2] Gheyath K Nasrallah,et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study , 2022, The Lancet Microbe.
[3] Gheyath K Nasrallah,et al. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants , 2022, The New England journal of medicine.
[4] L. Abu-Raddad,et al. COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar , 2022, Journal of global health.
[5] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[6] J. Malek,et al. Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance , 2022, Environmental Technology & Innovation.
[7] L. Abu-Raddad,et al. COVID-19 Disease Severity in Children Infected with the Omicron Variant , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] A. Pottegård,et al. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study , 2022, BMJ.
[9] Gheyath K Nasrallah,et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.
[10] Gheyath K Nasrallah,et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.
[11] Gheyath K Nasrallah,et al. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections , 2022, medRxiv.
[12] Gheyath K Nasrallah,et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.
[13] Gheyath K Nasrallah,et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.
[14] S. Pilz,et al. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity , 2022, Environmental Research.
[15] L. Abu-Raddad,et al. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar , 2022, The New England journal of medicine.
[16] Gheyath K Nasrallah,et al. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[17] L. Abu-Raddad,et al. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.
[18] M. Rämet,et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age , 2021, The New England journal of medicine.
[19] L. Abu-Raddad,et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.
[20] L. Abu-Raddad,et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. , 2021, JAMA.
[21] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[22] L. Abu-Raddad,et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.
[23] J. Klausner,et al. A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection , 2021, medRxiv.
[24] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[25] L. Abu-Raddad,et al. Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar , 2021, medRxiv.
[26] Gheyath K Nasrallah,et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar , 2021, Nature Medicine.
[27] Gheyath K Nasrallah,et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses , 2021, Journal of travel medicine.
[28] J. Malek,et al. One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar , 2021, Frontiers in Cellular and Infection Microbiology.
[29] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[30] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[31] Gheyath K Nasrallah,et al. SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.
[32] L. Abu-Raddad,et al. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.
[33] C. Vogels. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern v3 , 2021 .
[34] Oluwaseun O. Ogunbiyi,et al. COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar , 2021, Science of The Total Environment.
[35] R. Bertollini,et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.
[36] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[37] R. Bertollini,et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 , 2020, medRxiv.
[38] James M Robins,et al. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.
[39] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[40] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .